Proteome Sciences secures further clinical contract

(Sharecast News) - Proteome Sciences said on Monday that it had secured a further significant clinical contract linked to its target engagement and chemoproteomics platform.

See latest RNS on InvestegateThe AIM-traded company said it expected the contract to act as a precursor to a new clinical trial programme due to start later in 2026.

Executive chairman Christopher Pearce said momentum and growth in Proteome's chemoproteomics services was continuing this year, adding that the company had generated "considerable interest and attention" at the recent American Society for Mass Spectrometry meeting in San Diego.

At 1016 BST, shares in Proteome Sciences were up 9.27% at 1.65p.

Reporting by Josh White for Sharecast.com.

See latest RNS on Investegate

Proteome